miRNA-Regulated Gene Vector for Specific Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches face challenges in achieving specific and stable transgene expression in targeted cell types due to issues with vector titer reduction, immune-mediated rejection, and 'leaky' promoter activity, particularly when using lentiviral vectors for in vivo administration.
Innovation Solution
Development of gene transfer vectors regulated by endogenously expressed microRNAs (miRNAs) to achieve specific and controlled transgene expression by incorporating miRNA target sequences, allowing for precise cell-type specificity and avoiding immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Length of moving object
If tissue-specific promoters are used to restrict transgene expression to target cell types, then cell specificity is improved, but expression strength and reliability deteriorate due to weak promoter activity and leaky expression
Solution Approach 1:
The invention changes the regulatory mechanism from transcriptional control (promoters) to post-transcriptional control (miRNA binding). By incorporating miRNA target sequences into the 3' UTR of the transgene, the system achieves cell-type specificity through miRNA-mediated repression while maintaining strong constitutive promoter activity, thereby resolving the contradiction between specificity and expression strength
Solution Approach 2:
The invention introduces miRNA target sequences as an intermediary element between the promoter and transgene. This intermediary allows the constitutive promoter to drive strong expression while miRNAs provide the cell-type specificity filter, eliminating the need for weak tissue-specific promoters and achieving both high expression and specificity simultaneously
2Length of moving object
If targeted envelope proteins are used to direct vectors to specific cell types, then cell targeting is improved, but vector titer and infectivity deteriorate
Solution Approach 1:
The invention extracts the cell-type specificity function from the envelope protein and transfers it to the miRNA regulatory system. By using ubiquitous envelope proteins for broad tropism combined with miRNA-mediated post-transcriptional repression, the system achieves cell-type specificity without the productivity loss associated with targeted envelopes
Solution Approach 2:
Instead of targeting delivery to specific cells (positive selection), the invention inverts the approach by delivering to all cells and then repressing expression in non-target cells (negative selection). This inversion using miRNA repression maintains high vector titer while achieving specificity, resolving the contradiction with targeted envelopes
3Power
If constitutive promoters are used to drive transgene expression, then expression strength is improved, but cell-type specificity deteriorates due to expression in all transduced cells
Solution Approach 1:
The invention segments the gene expression control into two independent modules: a constitutive promoter module for driving strong transcription and a miRNA target sequence module for post-transcriptional repression. This segmentation allows each module to perform its specialized function optimally, achieving both strong expression and cell-type specificity
Solution Approach 2:
The miRNA target sequence acts as an intermediary between the constitutive promoter and the transgene protein. It allows the promoter to function at full strength while the miRNA intermediary provides the cell-type specificity filter, resolving the contradiction between expression strength and specificity
4Productivity
If transgene expression is allowed in all transduced cells, then vector infectivity is improved, but immune-mediated rejection increases due to off-target expression
Solution Approach 1:
The invention applies preliminary anti-action by pre-installing miRNA target sequences into the transgene that will repress expression in non-target cells before the immune system can recognize off-target expression. This preventive measure maintains high infectivity while blocking the pathway to immune-mediated rejection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The miRNA-regulated vectors enable stringent control of transgene expression, reducing immune-mediated rejection and maintaining high vector infectivity, with demonstrated long-lasting expression in targeted tissues and reduced off-target effects.
Implementation Method 1
vectors can be designed to be regulated by endogenous miRNAs for controlling transgene expression
Data Source
AI summary
A gene vector comprising a miRNA sequence target.